We are live on ! Find out more
VYGR icon

Voyager Therapeutics

70 hedge funds and large institutions have $145M invested in Voyager Therapeutics in 2022 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 17 increasing their positions, 18 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,427% more call options, than puts

Call options by funds: $834K | Put options by funds: $33K

1% more funds holding

Funds holding: 6970 (+1)

8% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 13

2% more capital invested

Capital invested by funds: $143M → $145M (+$2.48M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.3% less ownership

Funds ownership: 62.45%62.15% (-0.3%)

6% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 18

Holders
70
Holders Change
+1
Holders Change %
+1.45%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
14
Increased
17
Reduced
18
Closed
13
Calls
$834K
Puts
$33K
Net Calls
+$801K
Net Calls Change
-$3.23M
Name Holding Trade Value Shares
Change
Change in
Stake
TGI
1
TRV GP III
Massachusetts
$33.1M
EC
2
EcoR1 Capital
California
$29M
AC
3
Armistice Capital
New York
$20.7M
Vanguard Group
4
Vanguard Group
Pennsylvania
$11.9M +$332K +58,358 +3%
EAM
5
Erste Asset Management
Austria
$6.86M
BlackRock
6
BlackRock
New York
$5.14M +$1.43M +252,420 +43%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$4.86M -$264K -46,390 -5%
D.E. Shaw & Co
8
D.E. Shaw & Co
New York
$4.2M -$91.3K -16,076 -2%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$4.08M +$620K +109,189 +20%
Federated Hermes
10
Federated Hermes
Pennsylvania
$3.69M -$773 -136 -0%
JP Morgan Chase
11
JP Morgan Chase
New York
$1.96M
Millennium Management
12
Millennium Management
New York
$1.7M -$251K -44,221 -14%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$1.66M +$9.75K +1,716 +0.6%
Morgan Stanley
14
Morgan Stanley
New York
$1.63M -$456K -80,200 -23%
FT
15
Fiduciary Trust
Massachusetts
$1.52M
Citadel Advisors
16
Citadel Advisors
Florida
$988K -$344K -60,540 -27%
Susquehanna International Group
17
Susquehanna International Group
Pennsylvania
$849K +$405K +71,323 +105%
Renaissance Technologies
18
Renaissance Technologies
New York
$728K +$14.2K +2,500 +2%
Connor, Clark & Lunn Investment Management (CC&L)
19
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$710K +$24.1K +4,250 +4%
RJA
20
Raymond James & Associates
Florida
$670K +$625K +109,910 New
CANY
21
Caxton Associates (New York)
New York
$651K -$170K -29,896 -22%
BCM
22
Bridgeway Capital Management
Texas
$621K
Bank of New York Mellon
23
Bank of New York Mellon
New York
$601K -$1.3K -229 -0.2%
State Street
24
State Street
Massachusetts
$542K
Citigroup
25
Citigroup
New York
$513K +$459K +80,749 +2,459%

VYGR Hedge Fund Activity: Q4 2022 in Review

70 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q4 2022, worth a combined $145M — up 1.7% from $143M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new VYGR positions and 13 closed out — a net gain of 1 holder — while 17 added to existing stakes and 18 trimmed.

The largest buyer was BlackRock, adding an estimated $1.43M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $1.71M sold.

  • 70 institutional investors held Voyager Therapeutics (VYGR) as of Q4 2022, up from 69 in Q3 2022.
  • Funds reported $145M of Voyager Therapeutics stock for Q4 2022, up 1.7% quarter-over-quarter.
  • 14 funds opened new Voyager Therapeutics positions in Q4 2022 and 13 closed out, a net change of +1 holder.
  • The largest Voyager Therapeutics buyer in Q4 2022 was BlackRock, an estimated $1.43M added.
  • The largest Voyager Therapeutics seller in Q4 2022 was Point72 Asset Management, an estimated $1.71M sold.

Based on aggregated 13F filings for Q4 2022.